HCPLive

DECEMBER 30, 2024

Panelists discuss the new health measures relevant to chronic kidney disease (CKD) management and their significance in improving patient care and outcomes.

Kidney Disease 105

Kidney Disease Patient Care Outcomes 105

The New England Journal of Medicine

FEBRUARY 19, 2025

Chronic kidney disease affects 14% of the U.S. population1 and is associated with an extraordinarily high risk of poor outcomes, including progression to end-stage kidney disease, cardiovascular events, and death.2

Kidney Disease 48

Kidney Disease Outcomes 48

The New England Journal of Medicine

MARCH 28, 2025

Among participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, oral semaglutide (14 mg) was associated with a lower risk of cardiovascular events than placebo after 4 years of follow-up.

Diabetes 75

Diabetes Kidney Disease Cardiovascular Disease Outcomes 75

Med Page Today

APRIL 15, 2024

(MedPage Today) -- A multi-pronged electronic health record-based population health management intervention failed to move the needle for slowing chronic kidney disease (CKD) progression, a cluster randomized trial showed. Over a median follow.

Kidney Disease 82

Kidney Disease Outcomes 82

HCPLive

NOVEMBER 25, 2024

Panelists discuss how early detection of chronic kidney disease (CKD) in stages 2 and 3 can improve patient outcomes across various specialties, including nephrology, cardiology, and primary care.

Kidney Disease 98

Kidney Disease Outcomes 98

The British Journal of Cardiology

MARCH 4, 2025

Acute coronary syndrome (ACS) events in people receiving long-term haemodialysis (HD) are common, present atypically and are associated with poor outcomes. 57 These are some of the reasons that the combination of cardiac and renal disease strike fear into even the most seasoned clinicians.

Kidney Disease 45

Kidney Disease Outcomes Article 45

HCPLive

AUGUST 31, 2024

Kenneth Mahaffey, MD, discusses FLOW trial data showing semaglutide improves cardiovascular outcomes in patients with type 2 diabetes, regardless of CKD severity.

Kidney Disease 72

Kidney Disease Diabetes Outcomes 72

American College of Cardiology

MARCH 29, 2025

The goal of the phase 3b SOUL trial was to assess the cardiovascular efficacy of oral semaglutide, a GLP-1 receptor agonist, and to determine the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both.

Kidney Disease 58

Kidney Disease Outcomes Cardiovascular Disease Diabetes 58

Journal of the American Heart Association

DECEMBER 24, 2024

BackgroundThis realworld evidence study compared risks of cardiovascular events in hospital settings among patients with chronic kidney disease (CKD) with and without hyperkalemia.Methods and ResultsAdults with CKD stages 3b/4 with and without hyperkalemia were identified from Optum's deidentified Market Clarity Data (January 2016August 2022).

Kidney Disease 45

Kidney Disease Arrhythmia Myocardial Infarction Atrial Fibrillation 45

HeartRhythm

SEPTEMBER 11, 2024

End-stage kidney disease (ESKD) patients are prone to bloodstream infections which may result in a higher risk of cardiac implantable electronic device (CIED) infections.

Kidney Disease 40

Kidney Disease Outcomes 40

HCPLive

JUNE 6, 2024

Alexandra Louise Møller, MS, PhD, discusses the results of a PROVALID analysis examining the predictive value of endotrophin levels for predicting CKD events.

Kidney Disease 52

Kidney Disease Diabetes Outcomes 52

Hypertension Journal

DECEMBER 5, 2024

BACKGROUND:Intensive blood pressure (BP) control in youth with chronic kidney disease (CKD) slows progression, delaying the need for kidney replacement therapy (KRT). Hypertension, Ahead of Print. Most youth with CKD have hypertension and BP control is difficult to achieve outside of controlled experimental settings.

Blood Pressure 45

Blood Pressure Kidney Disease Pediatrics Hypertension 45

HeartRhythm

NOVEMBER 28, 2024

Patients with chronic kidney disease (CKD) on renal replacement therapy (RRT) are at high risk for cardiovascular implantable electronic device (CIED) infections. Although device extraction is standard management, it is often avoided in these patients due to high procedural risks.

Kidney Disease 40

Kidney Disease Outcomes 40

HeartRhythm

JULY 15, 2024

Limited data are available on leadless pacemaker (LPM) outcomes according to different stages of chronic kidney disease (CKD).

Kidney Disease 40

Kidney Disease Pacemaker Outcomes 40

European Journal of Heart Failure

JANUARY 17, 2025

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: a FIDELITY analysis. c CV composite outcome component(s). d Composite of time to kidney failure, sustained 57% decrease in eGFR from baseline over 4weeks, or kidney-related death. thiazide diuretics).

Kidney Disease 40

Kidney Disease Diabetes Myocardial Infarction Heart Failure 40

Open Heart

OCTOBER 31, 2024

Results Baseline characteristics revealed significant differences between NUA and HUA groups, with the latter exhibiting a higher prevalence of males, chronic kidney disease (CKD) and elevated levels of various biomarkers. Our findings suggest that monitoring and managing SUA could be crucial in improving patient with HF outcomes.

Heart Failure 52

Heart Failure Kidney Disease Blood Pressure Biomarkers 52

Frontiers in Cardiovascular Medicine

FEBRUARY 27, 2024

Background Chronic Kidney Disease (CKD) stands as a formidable health challenge, recognized not only for its growing prevalence but also for its association with elevated mortality rates. Emerging evidence suggests that CKD is inherently linked to inflammatory processes, marking it as an inflammatory disorder.

Kidney Disease 59

Kidney Disease Cardiovascular Disease Outcomes 59

Cardiovascular Diabetology

JULY 3, 2024

Despite improved glycemic treatment, the impact of glycation on pathological consequences may persist and contribute to adverse clinical outcomes in diabetes. In the present study we.

Diabetes 64

Diabetes Kidney Disease Outcomes Research 64

European Journal of Heart Failure

FEBRUARY 5, 2025

Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis. However, the evidence on the benefits of ARNI in HF patients with end-stage kidney disease (ESKD) undergoing dialysis is limited.

Kidney Disease 49

Kidney Disease Heart Failure Preserved Ejection Fraction Blood Pressure 49

HCPLive

MAY 16, 2024

Clark-Cutaia, PhD, ACNP-BC, RN, highlights strategies to improve cardiovascular disease-related outcomes in patients with ESKD.

RN 59

RN Kidney Disease Cardiovascular Disease Outcomes 59

Coronary Artery Disease Journal

JUNE 18, 2024

Background Advanced chronic kidney disease (ACKD) is common in patients undergoing percutaneous coronary intervention (PCI) and is associated with adverse outcomes. These patients are often excluded from revascularization studies. The goal of this study was to evaluate the impact of ACKD in patients undergoing PCI.

Kidney Disease 40

Kidney Disease Inpatient Outcomes Research 40

HeartRhythm

NOVEMBER 5, 2024

Chronic kidney disease (CKD) and kidney failure with replacement therapy (KFRT) are prevalent in patients with atrial fibrillation (AF).

Kidney Disease 40

Kidney Disease Atrial Fibrillation Outcomes 40

Med Page Today

MARCH 10, 2025

(MedPage Today) -- Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization's updated clinical practice guideline. In a synopsis of the recently published guideline -- serving.

Kidney Disease 68

Kidney Disease Outcomes 68

DAIC

JANUARY 8, 2025

a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, hasannounced that the U.S. The primary outcome measure is absolute change in the frequency of apnea-hypopnea episodes. tim.hodson Wed, 01/08/2025 - 14:11 Jan.

Blood Pressure 52

Blood Pressure Hypertension Kidney Disease BMI 52

HCPLive

OCTOBER 26, 2024

in the composite primary outcome of kidney failure, serious eGFR decline, or death compared to placebo. Participants receiving semaglutide had an overall hazard ratio of 0.76

Kidney Disease 52

Kidney Disease Diabetes Outcomes 52

HCPLive

MARCH 25, 2024

Chronic kidney disease was linked to increased mortality, higher costs, and the need for mechanical ventilation among hospitalized patients with sickle cell disease.

Sickle Cell Disease 59

Sickle Cell Disease Hospital Kidney Disease Outcomes 59

Journal of the American Heart Association

MARCH 13, 2025

Main outcome was SCA identified byInternational Classification of Diseases, Tenth Revision (ICD10).Participants The influence of proteinuria on SCA was stronger in advanced chronic kidney disease (stage 3 and stage 45).ConclusionsProteinuria Urine protein was measured using the spot urine dipstick method.

Cardiac Arrest 73

Cardiac Arrest Kidney Disease Risk Factors Outcomes 73

DAIC

APRIL 6, 2024

As evidence has mounted pointing to their benefits in reducing heart failure and other forms of heart disease, researchers have sought to determine whether these drugs could help to prevent heart failure even in people without diabetes or chronic kidney disease. Researchers tracked outcomes for a median of just under 18 months.

Heart attacks 81

Heart attacks Heart Attack Heart Failure Outcomes 81

Journal of the American Heart Association

DECEMBER 18, 2023

BackgroundBoth nighttime systolic blood pressure and pulse rate are associated with adverse outcomes in patients with chronic kidney disease (CKD). Cox regression was used to explore the association between nighttime DP and adverse outcomes.

Kidney Disease 40

Kidney Disease Hypertension Blood Pressure Risk Factors 40

DAIC

JUNE 28, 2024

milla1cf Fri, 06/28/2024 - 19:07 June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa , its flagship health equity initiative, to target a broader range of non-communicable diseases (NCDs), including chronic kidney disease (CKD) as well as hypertension and cardiovascular disease.

Kidney Disease 111

Kidney Disease Blood Pressure Cardiovascular Disease Hypertension 111

American College of Cardiology

DECEMBER 23, 2024

The goal of the EMPA-KIDNEY trial was to assess the safety and efficacy of empagliflozin in improving cardiac and renal outcomes among patients with chronic kidney disease (CKD).

Kidney Disease 58

Kidney Disease Outcomes Article 58

The British Journal of Cardiology

JULY 17, 2024

2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”

Kidney Disease 40

Kidney Disease Outcomes Diabetes Heart Failure 40

The American Journal of Cardiology

OCTOBER 23, 2024

Publication date: Available online 22 October 2024 Source: The American Journal of Cardiology Author(s): Nathan W. Kong, Joseph M. Kim, Anna K. Krawisz, Patrick Heindel, Archana Tale, Yang Song, Jeffrey L. Weinstein, Mohamad A. Hussain, Eric A.

Kidney Disease 40

Kidney Disease Medicare Outcomes 40

Circulation

MARCH 9, 2025

Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors. Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025.

Kidney Disease 83

Kidney Disease Biomarkers Heart Failure Risk Factors 83

Hypertension Journal

SEPTEMBER 14, 2023

BACKGROUND:Hypertension frequently accompanies chronic kidney disease (CKD) as etiology and sequela. Hypertension, Volume 80, Issue 12 , Page 2533-2543, December 1, 2023. We defined CKD as a sustained estimated glomerular filtration rate value <60 mL/min per 1.73 m2or a urine albumin-to-creatinine ratio ≥30 mg/g.

Kidney Disease 40

Kidney Disease Hypertension Blood Pressure Outcomes 40

European Journal of Heart Failure

OCTOBER 18, 2023

Mineralocorticoid receptor antagonist (MRA) use in severe chronic kidney disease and heart failure with reduced ejection fraction (HFrEF). CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio. m 2 , respectively. An eGFR ≥60 ml/min/1.73 m

Kidney Disease 40

Kidney Disease Heart Failure Hospital Outcomes 40

Stroke Journal

OCTOBER 10, 2023

BACKGROUND:Patients with end-stage kidney disease undergoing dialysis are at significant risk of stroke. Whether dialysis modality is associated with cerebrovascular disease is unclear. The primary outcome was incident acute ischemic stroke. Stroke, Volume 54, Issue 12 , Page 3054-3063, December 1, 2023.

Kidney Disease 40

Kidney Disease Stroke Strokes Cerebrovascular Disease 40